SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Checklist collage banner with halftone hands. Hand holding marker and putting a check mark or cross in checkbox. Collage design with halftone elements. Concept of check list. Vector illustration.
Vaccines
Pfizer ‘Confident’ in Valneva-Partnered Lyme Vaccine Despite Missed Primary Endpoint
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% efficacy against the tick-borne disease in a Phase 3 trial—but failed to hit a predetermined confidence interval.
March 23, 2026
 · 
2 min read
 · 
Heather McKenzie
Illustration showing a handshake, signaling cooperation, goodwill
Immunology and inflammation
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
Kali Therapeutics’ T cell engager, for which Sanofi is initially paying $180 million, could potentially be developed for a range of B cell–driven autoimmune disorders.
March 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Parkinson’s disease
FDA Warns of Seizure Risk With Some Parkinson’s Drugs
The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking carbidopa/levodopa drugs. Both AbbVie and Novartis market levodopa-based products.
March 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.
Funding
Backed by Sanofi, Pfizer, Earendil Bags $787M for AI-Driven Biologics Design
Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have attracted a pair of partnership agreements with Sanofi.
March 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Brain neuro cell growth or damaging drawing with texture shading illustration isolated on dark background
Parkinson’s disease
Oryon Splashes Onto Parkinson’s Scene With $42M for Cell Therapy
Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with Parkinson’s disease. Phase 1b/2a data showed that the asset can improve motor function and mobility in patients.
March 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Hourglass lying on pink background - Concept of time and woman
Insights
Validated Mechanisms, Strong Data Beat Hype in Longevity Investing
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing aging as an abstract target and concentrate on specific mechanisms that can clearly target specific, age-related diseases, according to two investors in a discussion with BioSpace.
March 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Sponsored
Powering the Next Wave of Cell Therapy: From iPSC-Derived Cells to In Vivo Reprogramming
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and manufacturing-ready reagent platforms are reshaping regenerative medicine and oncology. Recombinant antibodies and drug targets, e.g. endotoxin-free proteins, transmembrane proteins, and site-specifically labeled biomolecules are emerging as indispensable enablers of reproducibility, mechanistic insight, and clinical-scale success.
March 23, 2026
 · 
4 min read
Female ear in paint close-up. Copy space. Torn paper, blue background. The concept of eavesdropping, espionage, gossip and the yellow press.
Gene therapy
Gene Therapies for Hearing Loss Strike an Encouraging Note in Embattled Modality
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential billion-dollar market and banking on local delivery and the small amount of drug required to overcome key safety concerns.
March 23, 2026
 · 
7 min read
 · 
Tristan Manalac
Businessman confuse others with jargon in speech bubble dialogue
FDA
9 Months In, FDA’s New Priority Voucher Program Still Clouded With Uncertainty
The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma leaders try to decode the criteria for investigational or approved drugs to receive a voucher.
March 23, 2026
 · 
7 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS